Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$5.86 – $47.00
8% from low
Borrow rate
29.01%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $106.0K | $9.0M | $33.4M | $76.1M | $59.5M | $14.5M |
| Cost of revenue | $25.9K | $35.0K | $6.6M | $20.1M | $58.3M | $47.0M | $8.2M |
| Gross profit | −$25.9K | $71.0K | $2.4M | $13.3M | $17.7M | $12.5M | $6.3M |
| Gross margin | — | 67.0% | 27.0% | 39.7% | 23.3% | 21.0% | 43.3% |
| R&D | $21.0K | $78.0K | $132.0K | $388.0K | $62.0K | $418.0K | $238.0K |
| Operating income | −$2.8M | −$14.3M | −$19.0M | −$47.2M | −$50.4M | −$15.6M | −$4.5M |
| EBITDA | −$2.8M | −$14.2M | −$20.9M | −$17.9M | −$45.9M | −$15.1M | −$3.8M |
| Net income | −$2.8M | −$14.2M | −$21.2M | −$52.4M | −$57.0M | −$15.9M | −$119.7M |
| Net margin | — | -13367.9% | -236.6% | -156.9% | -75.0% | -26.7% | -825.8% |
| EPS (diluted) | -0.65 | -8.13 | -6.52 | -13.73 | -7.33 | -1.30 | 0.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $41M | $-0.65 | $-0.80–$-0.50 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds FLGC.
No tracked institution reports a position in FLGC as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-08-04 | 1-for-39reverse |
| 2023-06-09 | 1-for-20reverse |
No one on the platform has traded FLGC yet.
| $2M |
| — |
| ENSCEnsysce Biosciences, Inc. | $0.30 | +6.33% | $3M | — |
| KALAKALA BIO, Inc. | $2.52 | -1.18% | $55M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.8× sales vs its 54.4× historical median P/S.
Fair value ≈ $636.86 · price $8.95 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.